Sustained-Release Antipsychotic Approved for Schizophrenia

Invega Sustenna injected once monthly

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Aug. 3, 2009 (HealthDay News) -- Invega Sustenna (paliperidone palmitate) has been approved by the U.S. Food and Drug Administration to treat schizophrenia, drug maker Janssen said in a news release.

The longer-acting version of the previously approved drug should help prevent relapses commonly caused when schizophrenia patients fail to take a more frequent dose, the company said. Invega Sustenna is the first once-monthly injectable atypical antipsychotic approved in the United States for this use, said the release from Janssen, a division of New Jersey-based Ortho-McNeil-Janssen Pharmaceuticals.

Common side effects of the drug include injection site reactions, fatigue and dizziness, Janssen said. The drug should be used with caution by people who have any history of seizure disorder, diabetes or low white cell count.

Schizophrenia, for which there is no cure, is a severe brain disorder that affects about 1.1 percent of the U.S. adult population, the U.S. National Institutes of Health says. People with schizophrenia sometimes hear voices and may become convinced that others plan to hurt them.

More information

The FDA has more about this drug's history.


Last Updated: